{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:29:12Z","timestamp":1789525752996,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Everfront Biotech Inc., Taiwan, ROC","award":["ndhu 103A037"],"award-info":[{"award-number":["ndhu 103A037"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.neuropharm.2017.02.014","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T05:02:14Z","timestamp":1487653334000},"page":"434-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["n-Butylidenephthalide exhibits protection against neurotoxicity through regulation of tryptophan 2, 3 dioxygenase in spinocerebellar ataxia type 3"],"prefix":"10.1016","volume":"117","author":[{"given":"Karthyayani","family":"Rajamani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Han","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Tsang","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng-Huwei","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1301-8213","authenticated-orcid":false,"given":"Dean-Kuo","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinn-Zong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horng-Jyh","family":"Harn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzyy-Wen","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.02.014_bib1","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/hmg\/11.9.1075","article-title":"YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit","volume":"11","author":"Cemal","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib2","doi-asserted-by":"crossref","first-page":"9310","DOI":"10.1073\/pnas.152101299","article-title":"Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis","volume":"99","author":"Chai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib3","doi-asserted-by":"crossref","first-page":"12713","DOI":"10.1523\/JNEUROSCI.3909-08.2008","article-title":"Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3","volume":"28","author":"Chen","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fphar.2016.00112","article-title":"The role of butylidenephthalide in targeting the microenvironment which contributes to liver fibrosis amelioration","volume":"7","author":"Chuang","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.nbd.2007.06.005","article-title":"A\u00a0mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice","volume":"27","author":"Colomer Gould","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0197-0186(95)00091-7","article-title":"The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits","volume":"28","author":"de Carvalho","year":"1996","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib7","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1021\/jm2006782","article-title":"Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators","volume":"54","author":"Dolusic","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib8","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.410390411","article-title":"Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features","volume":"39","author":"Durr","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib9","doi-asserted-by":"crossref","first-page":"e85305","DOI":"10.1371\/journal.pone.0085305","article-title":"n-butylidenephthalide protects against dopaminergic neuron degeneration and alpha-synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease","volume":"9","author":"Fu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.02.014_bib10","doi-asserted-by":"crossref","first-page":"10266","DOI":"10.1523\/JNEUROSCI.2734-04.2004","article-title":"A\u00a0mutant Ataxin-3 putative-cleavage fragment in brains of machado-joseph disease patients and transgenic mice is cytotoxic above a critical concentration","volume":"24","author":"Goti","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib11","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-4658.2012.08485.x","article-title":"Quinolinic acid, the inescapable neurotoxin","volume":"279","author":"Guillemin","year":"2012","journal-title":"Febs J."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCRESAHA.112.265652","article-title":"Ryanodine receptor current amplitude controls Ca2+ sparks in cardiac muscle","volume":"111","author":"Guo","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/hmg\/ddi472","article-title":"Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3","volume":"15","author":"Haacke","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib14","doi-asserted-by":"crossref","first-page":"18851","DOI":"10.1074\/jbc.M611914200","article-title":"Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3","volume":"282","author":"Haacke","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.yjmcc.2009.10.005","article-title":"Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass","volume":"48","author":"Hilliard","year":"2010","journal-title":"J.\u00a0Mol. Cell Cardiol."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib16","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/hmg\/dds449","article-title":"Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3)","volume":"22","author":"Hubener","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ng0696-196","article-title":"Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in\u00a0vitro and in\u00a0vivo","volume":"13","author":"Ikeda","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF03033448","article-title":"Misfolding promotes the ubiquitination of polyglutamine-expanded ataxin-3, the defective gene product in SCA3\/MJD","volume":"6","author":"Jana","year":"2004","journal-title":"Neurotox. Res."},{"issue":"Pt 9","key":"10.1016\/j.neuropharm.2017.02.014_bib19","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/brain\/121.9.1687","article-title":"Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3","volume":"121","author":"Klockgether","year":"1998","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2017.02.014_bib20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature10671","article-title":"Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease","volume":"480","author":"Koch","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.02.014_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1212\/WNL.30.3.319","article-title":"Clinical criteria for diagnosis of Machado-Joseph disease: report of a non-Azorena Portuguese family","volume":"30","author":"Lima","year":"1980","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2017.02.014_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1471-4159.1996.66010203.x","article-title":"Serotonin 5-HT1D and 5-HT1A receptors respectively mediate inhibition of glutamate release and inhibition of cyclic GMP production in rat cerebellum in\u00a0vitro","volume":"66","author":"Maura","year":"1996","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib23","doi-asserted-by":"crossref","first-page":"8180","DOI":"10.1523\/JNEUROSCI.0340-10.2010","article-title":"L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease","volume":"30","author":"Peng","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0304-3940(00)00799-0","article-title":"Differential effects of L-trytophan and buspirone on biogenic amine contents and metabolism in Lurcher mice cerebellum","volume":"280","author":"Reader","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib25","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1023\/A:1020708319483","article-title":"Effects of L-tryptophan on indoleamines and catecholamines in discrete brain regions of wild type and Lurcher mutant mice","volume":"24","author":"Reader","year":"1999","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib26","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/0006-2952(95)00006-L","article-title":"The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat","volume":"49","author":"Salter","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-4613-0381-7_7","article-title":"The effects of a selective inhibitor of tryptophan 2,3-dioxygenase and a combined inhibitor of tryptophan 2,3-dioxygenase and 5-HT reuptake on serotonergic function in the rat","volume":"398","author":"Salter","year":"1996","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib28","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/brain\/aws177","article-title":"Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease","volume":"135","author":"Simoes","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2017.02.014_bib29","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1093\/hmg\/ddu209","article-title":"Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease","volume":"23","author":"Simoes","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib30","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/bph.12230","article-title":"The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders","volume":"169","author":"Stone","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib31","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.44.7.1302","article-title":"A\u00a0clinical and pathologic study of a large Japanese family with Machado-Joseph disease tightly linked to the DNA markers on chromosome 14q","volume":"44","author":"Takiyama","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2017.02.014_bib32","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/archneur.1997.00550180059013","article-title":"Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy","volume":"54","author":"Trouillas","year":"1997","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib33","doi-asserted-by":"crossref","first-page":"14912","DOI":"10.1073\/pnas.1203083109","article-title":"Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation","volume":"109","author":"van der Goot","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib34","first-page":"1706","article-title":"L-3-n-butylphthalide improves cognitive impairment of APP\/PS1 mice by BDNF\/TrkB\/PI3K\/AKT pathway","volume":"7","author":"Xiang","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.neuropharm.2017.02.014_bib35","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.neurobiolaging.2011.03.007","article-title":"Dl-3-n-butylphthalide, a natural antioxidant, protects dopamine neurons in rotenone models for Parkinson's disease","volume":"33","author":"Xiong","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2017.02.014_bib36","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.neuropharm.2012.02.014","article-title":"L-3-n-butylphthalide improves cognitive deficits in rats with chronic cerebral ischemia","volume":"62","author":"Xu","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.02.014_bib37","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.neurobiolaging.2011.03.007","article-title":"Dl-3-n-butylphthalide, a natural antioxidant, protects dopamine neurons in rotenone models for Parkinson's disease","volume":"33","author":"Zhang","year":"2012","journal-title":"Neurobiol. Aging"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081730059X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081730059X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T19:11:37Z","timestamp":1587409897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081730059X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":37,"alternative-id":["S002839081730059X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.02.014","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"n-Butylidenephthalide exhibits protection against neurotoxicity through regulation of tryptophan 2, 3 dioxygenase in spinocerebellar ataxia type 3","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}